Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03610945
- Locations
- ๐บ๐ธ
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States
Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 10
- Registration Number
- NCT03476317
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03451110
- Locations
- ๐บ๐ธ
Worldwide Clinical Trials, San Antonio, Texas, United States
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT03253094
- Locations
- ๐บ๐ธ
Drexel University, Philadelphia, Pennsylvania, United States
๐บ๐ธWake Research Associates, LLC, Raleigh, North Carolina, United States
๐บ๐ธNew Age Medical Research Corp., Miami, Florida, United States
A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT03135106
- Locations
- ๐ง๐ช
Clinical Pharmacology Unit, Merksem, Belgium
Treatment With Tamoxifen in Cryptococcal Meningitis
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2019-12-02
- Target Recruit Count
- 50
- Registration Number
- NCT03112031
- Locations
- ๐ป๐ณ
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
๐ป๐ณCho Ray Hospital, Ho Chi Minh City, Vietnam
๐ป๐ณHospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03028103
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
๐บ๐ธUniversity of Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Cryptococcal Antigen Screening Plus Sertraline
- Conditions
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT03002012
- Locations
- ๐บ๐ฌ
Infectious Disease Institute, Makerere University, Kampala, Uganda
Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 35
- Registration Number
- NCT02997059
- Locations
- ๐ซ๐ท
CHRU, Hรดpital Claude Huriez, Lille, France
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT02971007
- Locations
- ๐บ๐ธ
Lawrence OB/GYN, Lawrenceville, New Jersey, United States
๐บ๐ธAdvanced Research Institute Inc, New Port Richey, Florida, United States
๐บ๐ธPMG Research of Wilmington, LLC, Wilmington, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.